Smoothened antagonists reverse taxane resistance in ovarian cancer. - Wikidata - awgldk - TriplyDB

Smoothened antagonists reverse taxane resistance in ovarian cancer.

Smoothened antagonists reverse taxane resistance in ovarian cancer.

http://www.wikidata.org/entity/Q36084215

about

Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance Katanin localization requires triplet microtubules in Chlamydomonas reinhardtii Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling The role of GLI1 for 5-Fu resistance in colorectal cancer GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent Decitabine reactivated pathways in platinum resistant ovarian cancer.Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers Ovarian cancer stem cells: are they real and why are they important?Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.The Hedgehog pathway: role in cell differentiation, polarity and proliferation Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1 Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.Nonclassical hedgehog-GLI signaling and its clinical implications.Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.Sonidegib: First Global Approval.Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models.GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.Aberrant hedgehog signaling is responsible for the highly invasive behavior of a subpopulation of hepatoma cells.Emerging from their burrow: Hedgehog pathway inhibitors for cancer.The role of the SHH gene in prostate cancer cell resistance to paclitaxel.Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways.Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.Insights into the binding of paclitaxel to human serum albumin: multispectroscopic studies.The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.

P2860

Q26775006-EEBE8AEA-A3CE-48EA-BD85-07AF322B2C14 Q27320598-38F79C72-5E03-4168-A1C6-33AD63F1E22C Q28081405-250F5BA1-44EE-4002-8755-C7ACDDAC97EF Q30275354-E73AD975-F12F-4695-A0C9-E0D29EE28D76 Q30410019-43AC4C23-BA7D-41CC-805F-F62D7AAAA3E4 Q33559947-58FEFB9D-2E92-412F-A309-02D89C847D06 Q33560768-F3933004-AC0E-4A7D-B326-D1CC8B1E08C3 Q33689071-8E713151-7296-4062-AF1F-972EDC6492E7 Q33893928-EF03AAFF-2C20-4789-9A77-D260D701FB19 Q33976957-E0CA215B-74BB-498A-B768-9433494025FD Q34653337-0CA430C0-F807-469C-BF22-8D431AF02609 Q34706060-2DDB08F2-BD14-4227-85BA-8CDAF1B3566C Q35047699-DEAB74FD-0867-4803-B8D5-BC3D981F3C5E Q35678417-A89ECD4B-0648-4204-8967-7839D9C0CB8A Q35921565-8F990EA3-364D-4CF2-9837-7EAFF670EB0F Q36240079-4C585E2B-64C5-4D93-8568-AAB509DA8A05 Q36589159-FA0484F9-32A9-43F3-BA80-93BD4FAF59F8 Q36625295-609461D0-A7BF-47A3-9643-374828DAD98F Q36973762-29858509-FB3C-44F5-B553-690136F29C51 Q37378675-2999EE53-1FE5-4514-B11D-4F8BA7001C87 Q37381330-3A0AED01-E51E-426F-8380-180F2D3D0DB4 Q37702541-8EA25350-6490-48C4-839B-43A8D3207A60 Q37736262-D9B8E843-0DFF-4FE4-8902-BD2309CAD5E4 Q38034167-AEA0DCA7-8756-4A4C-BCC1-4347E70119A6 Q38127609-50F39D97-861E-42CF-94D4-D9F52407FFF7 Q38375504-4FA7B2C1-5166-4649-A4AE-129E901A0BE7 Q38577307-620870DF-C55A-4D11-8681-05E10EEA7459 Q38710041-5530C196-75F2-41DF-85FC-E435E1836370 Q38895410-49E89D7F-3378-42C7-BCEC-D92967506FB6 Q38899847-90419FD6-A6D1-4FA8-B1E2-A62EAACE6EF8 Q38908981-EC40AB29-40BF-4255-AD56-FB8CB09D8207 Q38985293-B70A631F-58F8-40C8-8F50-6BE893075CD6 Q39005862-D74B7A13-FBC0-4EAA-8B03-0D0011F6A5EC Q39163331-DB8300BC-A725-45FF-A0AB-096E0021BB06 Q46021160-2534C512-3B04-42FE-86E2-41FD4B636E41 Q46499769-93C38F02-60F3-4DF3-955D-800A1D37093E Q50993719-584E6BD0-1697-4CF2-A638-FBCFC3CF3055 Q53093918-D3AF8CD3-2820-47FD-8222-F723DCE91267

P2860

Smoothened antagonists reverse taxane resistance in ovarian cancer.

http://www.wikidata.org/entity/Q36084215

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@ast

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@en

type

label

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@ast

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@en

prefLabel

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@ast

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@en

P1433

Q36084215-775C95EA-08D3-41F5-9E6C-DEAE01447E1E

P1476

Q36084215-8091236F-40C0-4023-9ABA-5E19A3ABD690

P2093

Q36084215-11C8630A-CEE4-4F5F-8D5B-B3D76532ECE3

Q36084215-5C522165-A9FD-43A2-90FB-7D52C90F5008

Q36084215-6C87FA54-7489-40D8-961A-6E407D80BDF0

Q36084215-74F00AFB-6978-43F5-8934-9519F610297C

Q36084215-8269630C-4A22-481D-8492-5D72D3B60395

Q36084215-AF4E45C4-9EEB-409B-8452-92FF1CCE5159

Q36084215-BF6F99E6-CDEE-48B1-B358-E891E7949CF5

Q36084215-E91A4C61-E1A1-4B78-B680-20B0C988CF4A

P2860

Q36084215-165039F9-F322-42A9-8D34-4BD18AF7D194

Q36084215-229A48E0-AE3E-42C2-8CD6-CDB72EA66B53

Q36084215-24634647-E8D0-4A59-8B4A-2CBF0C5C1740

Q36084215-256E1C4F-7EE3-45BE-8BB3-D411393491B5

Q36084215-28B0C41F-F404-4E65-A9DB-B1057806B314

Q36084215-2C0D040F-19CF-4C24-85EB-BDB5B2DAE563

Q36084215-30983EDF-FE7B-4188-898A-D0053A9C56D5

Q36084215-3C4EB7A2-956C-4AC9-A101-B15A71A8F7C6

Q36084215-3C88B743-9D71-4957-B4D3-131DB62CF81F

Q36084215-46958A72-003C-42C0-B2D4-9C6D94CB6EDA

P304

Q36084215-13710D0E-7023-46DA-A033-E6F9BD0A78BA

P31

Q36084215-658AB095-4C62-489C-8605-F97AAFE2C6DB

P356

Q36084215-BD64C628-BDB6-445C-954F-865DEFF39E7B

P433

Q36084215-CF85829E-6C60-49BD-B854-F996638073FB

P478

Q36084215-98E60248-A9FC-47B0-A6BB-E72DC0C8AC1D

P577

Q36084215-9F1098A5-986F-4929-83D0-BBDB0F33413A

P698

Q36084215-4C835B6C-8FAC-4D1B-B0EE-CDED91C6AF93

P921

Q36084215-8F3D3C9C-9F9F-4EB5-9677-EB9BCEA48033

P932

Q36084215-3C158D80-8E9E-4089-AC5B-9DD475B5FF36

P356

1535-7163.MCT-11-1058

P1433

Molecular Cancer Therapeutics

P1476

Smoothened antagonists reverse taxane resistance in ovarian cancer.

@en

P2093

Adam D Steg

http://www.w3.org/2001/XMLSchema#string

Angela Ziebarth

http://www.w3.org/2001/XMLSchema#string

Ashwini A Katre

http://www.w3.org/2001/XMLSchema#string

Charles N Landen

http://www.w3.org/2001/XMLSchema#string

Kerri S Bevis

http://www.w3.org/2001/XMLSchema#string

Monjri M Shah

http://www.w3.org/2001/XMLSchema#string

Ronald D Alvarez

http://www.w3.org/2001/XMLSchema#string

Zachary C Dobbin

http://www.w3.org/2001/XMLSchema#string

P2860

TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened

Targeting Hedgehog--a cancer stem cell pathway

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer

Hedgehog signalling in cancer formation and maintenance.

Communicating with Hedgehogs.

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.

The Gli code: an information nexus regulating cell fate, stemness and cancer.

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival

P304

1587-1597

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-11-1058

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22553355

http://www.w3.org/2001/XMLSchema#string

P921

P932

3392529

http://www.w3.org/2001/XMLSchema#string